The good news is that the risk for thyroid cancer linked to GLP-1 drugs appears low, but higher detections in the first year, ...
News Medical on MSN2d
GLP-1RA initiation linked to new thyroid cancer diagnosesResearchers investigate the risk of incident thyroid cancer among patients treated with glucagon-like peptide-1 receptor ...
Medpage Today on MSN6d
More Thyroid Cancers Found After Starting GLP-1s: Researchers Think They Know WhyGLP-1 agonist initiators had a significantly higher likelihood of undergoing thyroid ultrasonography at 6 and 12 months, suggesting detection bias was behind the increased cancer diagnosis rate ...
HealthDay on MSN3d
No Link Seen Between GLP-1 Receptor Agonist Use and Thyroid Cancer(HealthDay News) — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term, according to a study published online in ...
Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based ...
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...
Glucagon-like peptide 1 receptor agonist use was not associated with an increased risk for thyroid cancer compared with use of dipeptidyl peptidase-4 inhibitors. HealthDay News — Glucagon-like peptide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback